Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 1:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 109 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bacterial Vaginosis Clear all
Completed Phase 2 Interventional Results available

Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)

NCT02971007
View directory record Official record
Conditions
Vulvovaginitis, Yeast Infection, Yeast Infection Vaginal, Candidiasis, Vulvovaginal
Interventions
Oral Encochleated Amphotericin B (CAMB), Fluconazole
Drug
Lead sponsor
Matinas BioPharma Nanotechnologies, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2018 · Synced Oct 3, 2026, 1:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis

NCT01926028
View directory record Official record
Conditions
Vulvovaginal Candidiasis
Interventions
NDV-3A, NDV-3, Placebo
Biological
Lead sponsor
NovaDigm Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
20
States / cities
Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 3, 2026, 1:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp

NCT06954493
View directory record Official record
Conditions
Vulvovaginal Candidiasis, Candida Infection, Vaginal Candidiasis
Interventions
Ibrexafungerp
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Rogers, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 3, 2026, 1:22 PM EDT
Completed Phase 2 Interventional Results available

Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis

NCT03253094
View directory record Official record
Conditions
Candida Vulvovaginitis
Interventions
Fluconazole, SCY-078
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Oct 3, 2026, 1:22 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)

NCT03734991
View directory record Official record
Conditions
Candida Vulvovaginitis
Interventions
Ibrexafungerp, Placebo
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
12 Years and older · Female only
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Oct 3, 2026, 1:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Validity of Patient-Collected Wet Mounts

NCT02641717
View directory record Official record
Conditions
Vaginal Discharge, Trichomonas, Candidiasis, Vaginosis, Bacterial, Vaginitis
Interventions
vaginal swab
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older · Female only
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2016 · Synced Oct 3, 2026, 1:22 PM EDT
Completed Not applicable Interventional

A Study to Evaluate the Effects of a Prebiotic and Probiotic Supplement to Provide Relief From Symptoms Associated With Bacterial Vaginosis and Yeast Infections.

NCT06665126
View directory record Official record
Conditions
Bacterial Vaginosis, Yeast Infection
Interventions
Prebiotic + Probiotic Supplement, Active Placebo Supplement, Excipient Placebo Supplement
Dietary Supplement
Lead sponsor
Happy V
Industry
Eligibility
25 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 3, 2026, 1:22 PM EDT
Terminated Early Phase 1 Interventional

LUXSOL(TM) Topical Cream for the Treatment of Symptomatic Bacterial Vaginosis; A Proof of Concept Study

NCT02197182
View directory record Official record
Conditions
Bacterial Vaginosis (BV)
Interventions
LUXSOL copper containing cream, Metronidazole gel
Drug
Lead sponsor
CDA Research Group, Inc.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Detroit, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 3, 2026, 1:22 PM EDT
Completed Phase 4 Interventional

Safety and Tolerability of Metronidazole Gel 1.3%

NCT02392026
View directory record Official record
Conditions
Vaginosis, Bacterial
Interventions
Metronidazole Gel
Drug
Lead sponsor
Insud Pharma
Industry
Eligibility
12 Years to 17 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
8
States / cities
Long Beach, California • Paramount, California • Bardstown, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Oct 3, 2026, 1:22 PM EDT
Completed Phase 3 Interventional Results available

Bacterial Vaginosis Home Screening to Prevent STDs

NCT00667368
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Metronidazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
15 Years to 25 Years · Female only
Enrollment
1,370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Oct 3, 2026, 1:22 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Diagnosing Bacterial Vaginosis/Vaginitis (BV) Using the Gynecologene Test Method

NCT02558179
View directory record Official record
Conditions
Vaginosis, Bacterial
Interventions
Not listed
Lead sponsor
American International Biotechnology
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
4
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 3, 2026, 1:22 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Efficacy Study of Preconception Treatment of an Asymptomatic Bacterial Infection in an Infertility Population

NCT01322971
View directory record Official record
Conditions
Vaginosis, Bacterial, Infertility, Miscarriage
Interventions
Metronidazole, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Oct 3, 2026, 1:22 PM EDT
Terminated Phase 4 Interventional Results available

A Randomized Controlled Trial of Treatment of Bacterial Vaginosis

NCT04578015
View directory record Official record
Conditions
Bacterial Vaginoses
Interventions
Metronidazole, Placebo
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 3, 2026, 1:22 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study of SYM-1219 to Treat Bacterial Vaginosis

NCT02147899
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
SYM-1219, Placebo
Drug
Lead sponsor
Symbiomix Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
16
States / cities
Birmingham, Alabama • San Diego, California • Clearwater, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 3, 2026, 1:22 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Lactobacillus Administered Vaginally in Women With Bacterial Vaginosis

NCT00635622
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
LACTIN-V, Placebo control substance
Drug
Lead sponsor
Osel, Inc.
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2009 · Synced Oct 3, 2026, 1:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Intravaginal Gel and Ovule Formulations of TOL-463

NCT01812889
View directory record Official record
Conditions
Vaginal Infection
Interventions
TOL-463 Vaginal ovule, TOL-463 Vaginal gel
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Oct 3, 2026, 1:22 PM EDT
Terminated Phase 1 Interventional

Treatment of Bacterial Vaginosis Prior to Active Labor and Infectious Morbidity

NCT03954990
View directory record Official record
Conditions
Bacterial Vaginoses
Interventions
Metronidazole Oral, Placebo Oral Tablet
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 3, 2026, 1:22 PM EDT
Completed Not applicable Interventional

Inflammation and Treatment of Bacterial Vaginosis Near Term

NCT00720291
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Metronidazole, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 27, 2018 · Synced Oct 3, 2026, 1:22 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

TOL-463 Phase 2 Study for Vaginitis

NCT02866227
View directory record Official record
Conditions
Bacterial Vaginosis, Vulvovaginal Candidiasis
Interventions
TOL-463
Drug
Lead sponsor
Toltec Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Birmingham, Alabama • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 3, 2026, 1:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of How Bacterial Vaginosis and Its Treatment Affects Cervical and Vaginal Tissue

NCT01347632
View directory record Official record
Conditions
Bacterial Vaginosis, Vaginal Discharge
Interventions
Metronidazole
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Oct 3, 2026, 1:22 PM EDT
Completed No phase listed Observational

Sexually Transmitted Infections Among African American Women Who Have Sex With Women

NCT01043081
View directory record Official record
Conditions
Sexually Transmitted Infections, HIV Infections
Interventions
Not listed
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Oct 3, 2026, 1:22 PM EDT
Terminated Phase 1Phase 2 Interventional

GoldenCareTM for the Treatment of Bacterial Vaginosis

NCT01762670
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
GoldenCare, Metronidazole
Drug
Lead sponsor
CDA Research Group, Inc.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
2
States / cities
Detroit, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 3, 2015 · Synced Oct 3, 2026, 1:22 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Improving Maternal and Child Health Through Point-of-care STI Testing

NCT07290439
View directory record Official record
Conditions
Treponema Pallidum Infection, Chlamydia Trachomatis Infection, Neisseria Gonorrheae Infection, Trichomonas Vaginalis Vaginitis, Sexually Transmitted Infection
Interventions
Point-of-care STI tests, Standard of care STI testing
Diagnostic Test
Lead sponsor
Emory University
Other
Eligibility
Female only
Enrollment
756 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 3, 2026, 1:22 PM EDT
Completed Phase 3 Interventional Results available

Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections

NCT03840616
View directory record Official record
Conditions
Recurrent Vulvovaginal Candidiasis
Interventions
Oteseconazole (VT-1161) 150mg capsule, Fluconazole 150mg capsule, Placebo
Drug
Lead sponsor
Mycovia Pharmaceuticals Inc.
Industry
Eligibility
12 Years and older · Female only
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
33
States / cities
Tucson, Arizona • Encino, California • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2022 · Synced Oct 3, 2026, 1:22 PM EDT